PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
Tidying up US stomach cancer approvals
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Two oncology floats to end the summer break
Bicara and DualityBio will soon test market appetite for new oncology issues.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
